PhoreMost with new CEO
He joined the biopharmaceutical company in January 2017 as Chief Business Officer and now he was appointed as its Chief. He succeeds Dr Chris Torrance, PhoreMost founder and former CEO. Torrance will serve as chairman of the board of directors.
Prior to PhoreMost, Torbett co-founded Activiomics Ltd, where he was Chief Operating Officer until the company was acquired by hVIVO in 2014. Prior to that, he worked at Piramed Pharma, which was sold to Roche in 2008.
Torbett has a BSc in Biology from the University of York and a PhD from the Protein Phosphorylation Laboratory at the Cancer Research UK London Research Institute, after which he completed postdoctoral training at the University of California San Francisco Cancer Center. In 2019, he was awarded an MBA from the Open University.